NCT00918476已完成1 期
A Phase 1, Open Label Fixed Sequence Study To Investigate The Effects Of Multiple Oral Doses Of Filibuvir On The Steady State Pharmacokinetics Of Oral Contraceptive Steroids In Healthy Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- AUCtau, Cmax, for LN and EE on Day 21 in Period 1 and Period 2.
研究概览
简要总结
The purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of ethinyloestradiol [EE] and levonorgestrel [LN], to assess the safety and tolerability of 600 mg BID of filibuvir in healthy women and to investigate the pharmacokinetics of 600 mg BID of filibuvir in healthy women.
详细描述
To investigate the effects of multiple oral doses of filibuvir on the steady state pharmacokinetics of oral contraceptive steroids in healthy female subjects.
研究设计
- 研究类型
- Interventional
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy female subjects between the ages of 18 and 45 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- •Subjects must have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period
- •Body Mass Index (BMI) of approximately 17.5 to 30.5 kg/m2; and a total body weight >45 kg.
- •Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
- •Must be willing to practice an alternative method of contraception for the duration of the study in addition to oral contraceptive use.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •Any medical reason which would contraindicate the administration of oral contraceptives (as per label). Including but not limited to history of unexplained vaginal bleeding, current breast cancer, active liver disease, uncontrolled hypertension, history of diabetes with vascular complications, history of venous thrombosis, stroke, ischemic heart disease, history of severe headaches with focal neurologic symptoms.
- •Female subjects of non-childbearing potential who meet the following criteria:
- •Post menopausal, aged between 45-55 who have been amenorrheic for >2 years and who meet the criteria for serum FSH levels (>30 IU/L), or
- •Females who have undergone a hysterectomy, or
- •Females who have undergone tubal ligation, or
- •Females who have undergone bilateral oophorectomy.
- •History of discontinued use of oral contraceptives for medical reasons.
- •History of febrile illness within 5 days prior to the first dose.
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
研究组 & 干预措施
1. filibuvir + Oral Contraceptives
Experimental
干预措施: filibuvir + Oral Contraceptives (Drug)
结局指标
主要结局
AUCtau, Cmax, for LN and EE on Day 21 in Period 1 and Period 2.
时间窗: 21 days
次要结局
- LN and EE - Tmax and t1/2 (if data permit) in Period 1 and Period 2. Filibuvir - AUCtau, Cmax, Cmin, and Tmax on Day 28 of Period 1 and Day 21 of Period 2.(21 days)
- Safety (AE, lab, vital, ECG, etc).(21 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male ParticipantsHealthyNCT02530060Janssen Pharmaceutical K.K.8
已完成
1 期
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionRheumatoid ArthritisNCT03417778Gilead Sciences20
已完成
2 期
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenAcquired Immune Deficiency Syndrome (AIDS)HIV InfectionsNCT01854775Gilead Sciences129
已完成
1 期
Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPARELPostoperative Pain ManagementNCT03485014Pacira Pharmaceuticals, Inc15
终止
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicNCT05556343Bristol-Myers Squibb18